Bayer and Daiichi Sankyo Advance New Prostate Cancer Combo in Early-Stage Trial

Bayer AG (BAYRY), Daiichi Sankyo Company (DSKYF) announced an update on their ongoing clinical study.

Study Overview: Daiichi Sankyo and Bayer are running a Phase 1 study called “A Phase 1, Multicenter Trial Evaluating the Safety, Tolerability, and Efficacy of Valemetostat (DS-3201) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC).” The goal is to see if combining valemetostat with darolutamide is safe and shows early signs of benefit in men whose prostate cancer has spread and no longer responds to hormone therapy. The study matters because mCRPC is a high-need, high-value oncology market, and any new effective combo could support future revenue growth for both companies.

Intervention/Treatment: The trial tests two cancer drugs. Valemetostat (DS-3201) is an experimental oral drug designed to block certain enzymes that help cancer cells grow. Darolutamide (marketed as Nubeqa by Bayer) is an approved oral hormone drug that blocks androgen receptors to slow prostate cancer. The purpose is to see if adding valemetostat to standard darolutamide produces stronger and still manageable treatment effects in mCRPC.

Study Design: This is an interventional study, meaning patients receive active treatment rather than just observation. All participants get the same drug combination, so there is a single treatment group and no randomization. The trial is open-label, so doctors and patients know which drugs are given. The study’s primary goal is treatment-focused: to find a safe dose range and collect early signals on how well the combo works in advanced prostate cancer.

Study Timeline: The study was first submitted in November 2025, marking the formal launch of the program and the start of site activation. As a Phase 1 trial in dose finding, the primary completion date will come once enough safety and early activity data are collected at different dose levels. The estimated full completion will follow later, after expanding into more patients at selected doses. The last update on February 2, 2026, signals that the protocol and status are current and that the trial is actively recruiting.

Market Implications: For investors, this update reinforces the strategic push of Daiichi Sankyo and Bayer deeper into prostate cancer, a large and competitive market that includes players like Pfizer, Astellas, and Johnson & Johnson. While Phase 1 data are early and high risk, positive signals could support the long-term growth story for Daiichi Sankyo’s oncology pipeline and extend the commercial life and reach of Bayer’s Nubeqa franchise. In the near term, the impact on stock prices is likely modest, but ongoing recruitment and fresh updates should support sentiment around both companies’ innovation pipelines, especially if early safety and activity readouts are favorable relative to other emerging combinations in mCRPC.

The study remains ongoing and updated, with further details available on the ClinicalTrials.gov portal.

To learn more about BAYRY’s potential, visit the Bayer AG drug pipeline page.